Olomoucine

Overview

Olomoucine is an ATP competitive inhibitor of CDK s. Olomoucine is a purine ( HY-34431 ) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC 50 =7 μM), CDK/p35 kinase ( IC 50 =3 μM) and ERK1/p44 MAP kinase ( IC 50 =25 μM). Olomoucine regulates cell cycle and shows anti-melanin tumor activity.

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Others | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-W011428
• CAS No.: 101622-51-9
• Molecular Formula: C15H18N6O
• Molecular Weight: 298.34
• Purity: 99.88%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution
• Availability: In-stock

Source

Original product source